Integra LifeSciences (NASDAQ:IART) Research Coverage Started at UBS Group

UBS Group started coverage on shares of Integra LifeSciences (NASDAQ:IART) in a research note released on Tuesday morning, MarketBeat reports. The brokerage issued a neutral rating and a $19.00 price objective on the life sciences company’s stock.

IART has been the subject of several other reports. Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Truist Financial increased their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Thursday, June 18th. Finally, BMO Capital Markets started coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Price Performance

Shares of IART opened at $17.10 on Tuesday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The company’s fifty day moving average price is $17.67 and its 200-day moving average price is $13.45. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The firm has a market capitalization of $1.33 billion, a PE ratio of -189.95, a price-to-earnings-growth ratio of 1.14 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.31% and a negative net margin of 0.44%.The company had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP raised its position in Integra LifeSciences by 1.3% during the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after acquiring an additional 100,000 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its position in Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares in the last quarter. Invesco Ltd. grew its stake in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after purchasing an additional 31,931 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after purchasing an additional 267,134 shares during the period. Finally, State Street Corp increased its holdings in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q2 earnings beat expectations: Integra reported adjusted earnings of $0.56 per share, up from $0.45 a year earlier and above the $0.48 consensus estimate. Revenue of $418.8 million was also slightly ahead of expectations. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst price target raised: Wells Fargo increased its target from $15 to $18 while maintaining an “equal weight” rating. The higher target signals improved valuation expectations, although the unchanged rating limits the bullish impact. Wells Fargo raises Integra price target
• Positive Sentiment: Technical momentum remains favorable: IART was identified as a potential breakout stock after trading near its 52-week high and passing technical screens, which may attract momentum-oriented investors. Stocks showing breakout potential
• Neutral Sentiment: Full-year outlook was maintained near consensus: Integra expects 2026 EPS of $2.40-$2.50 and revenue of approximately $1.7 billion, broadly matching analyst expectations.
• Neutral Sentiment: New analyst coverage: UBS began coverage of Integra, adding institutional attention; the available report does not specify its rating or price target. UBS begins coverage on Integra LifeSciences
• Negative Sentiment: Q3 guidance offers limited upside: EPS guidance of $0.53-$0.61 and revenue guidance of $410 million-$425 million bracket consensus estimates, suggesting expectations are largely embedded rather than being raised. Integra also reported a negative net margin, underscoring ongoing profitability concerns.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.